Zimmer Biomet (ZBH) PT Raised to $134 at Needham & Company
Get Alerts ZBH Hot Sheet
Rating Summary:
21 Buy, 22 Hold, 3 Sell
Rating Trend: Down
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 11
Join SI Premium – FREE
Needham & Company analyst Mike Matson reiterated a Buy rating and boosted his price target on Zimmer Biomet (NYSE: ZBH) to $134.00 (from $129.00).
Matson commented, "ZBH beat consensus revenue and EPS in 1Q16 and management raised guidance. Pro forma constant currency revenue growth improved to 1.2% in 1Q16 from 0.5% 4Q15 as growth improved across all of ZBH's businesses with the exception of Sports, Extremities, and Trauma (SET) and management's guidance for 2Q16 implies further acceleration. We expect accelerating revenue growth and EPS upside to drive ZBH's P/E multiple, and stock price, higher and we reiterate our Buy rating."
For an analyst ratings summary and ratings history on Zimmer Biomet click here. For more ratings news on Zimmer Biomet click here.
Shares of Zimmer Biomet closed at $115.89 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Teleperformance (TEP:FP) (TLPFY) PT Lowered to EUR125 at RBC Capital, 'perceived risk profile makes it a no-fly zone for many investors'
- TD Cowen Starts Grindr (GRND) at Buy
- 4D Molecular Therapeutics (FDMT) PT Lowered to $63 at BMO Capital, 'uncertainty remains a lingering overhang until the PhIII readout'
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeRelated Entities
Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!